First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

#4644

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Aim(s): To evaluate the efficacy and safety of radiopharmaceutical 177Lu-DOTA-TATE produced in the N.N. Blokhin National Medical Research Center of Oncology for patients with metastatic NEN G1-3.

Materials and methods: The study included 10 patients - 3 (30%) rectal NET, 1 (10%) gastric NET, 1 (10%) pancreatic NET, 1 (%) lung NET, 3 (30%) pheochromocytoma or paraganglioma, 1 (10%) NET of unknown primary site. 8 (80%) were classified as grade 2 and 2 (20%) – grade 3. The median Ki-67 was 12.5% (5-26). 50% of patients were male and 50% - female. The median number of previous lines of therapy was 3 (2-3). All patients had SSTR-positive disease assessed by 68Ga-DOTA-TATE PET/CT. The average administered activity of 177Lu-DOTA-TATE was 7.4 GBq, the interval between cycles was 8-10 weeks. 4 cycles are planned.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,